Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Budesonide  COVID-19 treatment studies for Budesonide  C19 studies: Budesonide  Budesonide   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 74% Improvement Relative Risk Ventilation 76% Hospitalization time 20% c19budesonide.com Gavriilidis et al. NCT05279391 Budesonide LATE Favors budesonide Favors control
Gavriilidis, 48 patient budesonide late treatment study: 74% lower mortality [p=0.05], 76% lower ventilation [p=0.02], and 20% shorter hospitalization [p=0.02] https://c19p.org/gavriilidis
copied to clipboard
Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure
Gavriilidis et al., Clinical Immunology, doi:10.1016/j.clim.2022.109016
18 Apr 2022    Source   PDF   Share   Tweet
Small retrospective study of hospitalized patients with severe respiratory failure, 22 treated with a combination of budesonide, tocilizumab, baricitinib, dornase alfa, and salbutamol or/and ipratropium, and 26 SOC patients, showing lower mortality and intubation with treatment. The average age of the combined treatment group was 6 years younger than the SOC group.
risk of death, 73.7% lower, RR 0.26, p = 0.045, treatment 2 of 22 (9.1%), control 9 of 26 (34.6%), NNT 3.9.
risk of mechanical ventilation, 76.4% lower, RR 0.24, p = 0.02, treatment 2 of 22 (9.1%), control 10 of 26 (38.5%), NNT 3.4.
hospitalization time, 19.6% lower, relative time 0.80, p = 0.02, treatment mean 15.6 (±5.3) n=22, control mean 19.4 (±7.2) n=26.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
This study is excluded in meta analysis: combined treatments may contribute more to the effect seen.
Gavriilidis et al., 4/18/2022, retrospective, Greece, Europe, peer-reviewed, 19 authors, study period 25 October, 2020 - 18 August, 2021, this trial uses multiple treatments in the treatment arm (combined with tocilizumab, baricitinib, dornase alfa, and salbutamol or/and ipratropium) - results of individual treatments may vary, trial NCT05279391.
Contact: pskendro@med.duth.gr, kritis@med.duth.gr.
All Studies   Meta Analysis
This PaperBudesonideAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit